SGMT earnings: next report 2026-08-12, real EPS beat/miss history, analyst consensus Buy, P/E -5.22. Updated 2026-07-23.
Sagimet Biosciences (SGMT) Research Hub
Sagimet Biosciences (SGMT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 10.88 USD (+0.18%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -5.22, market cap 0.23B. This hub links to the full technical, earnings and options research available for SGMT.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 10.88 USD (+0.18%) |
| 52-week range | 6.31 USD – 11.35 USD |
| Trend regime | Range |
| 14-day RSI | 72 (Overbought) |
| Trailing P/E | -5.22 |
| Market cap | 0.23B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for SGMT
Covered Call on SGMT: how it works, illustrative setup around the real 10.88 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SGMT: how it works, illustrative setup around the real 10.88 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SGMT: how it works, illustrative setup around the real 10.88 USD price, max profit/loss, breakeven and when to use it. Educational.
SGMT technical analysis: range, last 10.88 USD, RSI 72, 52w range 6.31 USD–11.35 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is SGMT in?
Sagimet Biosciences (SGMT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is SGMT in an uptrend or downtrend?
As of 2026-09-11, SGMT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SGMT's trailing P/E ratio?
SGMT's trailing P/E is -5.22, with a market cap of 0.23B. See the earnings research page for full valuation detail.
When does SGMT next report earnings?
SGMT is next scheduled to report earnings on 2026-08-12, with a consensus EPS estimate of -0.28 USD.